Department of Pediatric Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Saudi J Gastroenterol. 2012 Jan-Feb;18(1):26-33. doi: 10.4103/1319-3767.91735.
BACKGROUND/AIM: We aim to investigate the safety of outpatient blind percutaneous liver biopsy (BPLB) in infants and children with chronic liver disease (CLD).
BPLB was performed as an outpatient procedure using the aspiration Menghini technique in 80 infants and children, aged 2 months to 14 yrs, for diagnosis of their CLD. Patients were divided into three groups: Group 1 (<1 year), group 2 (1-6 yrs), and group 3 (6-14 yrs). The vital signs were closely monitored 1 hr before biopsy, and then 1, 2, 6, and 24 hrs after biopsy. Twenty-four hours pre- and post-biopsy complete blood counts, liver enzymes, prothrombin time (PT), and abdominal ultrasonography, searching for a biopsy-induced hematoma, were done for all patients.
No mortality or major morbidities were encountered after BPLB. The rate of minor complications was 17.5% including irritability or "pain" requiring analgesia in 10%, mild fever in 5%, and drowsiness for >6 hrs due to oversedation in 2.5%. There was a statistically significant rise in the 1-hr post-biopsy mean heart and respiratory rates, but the rise was non-significant at 6 and 24 hrs except for group 2 where heart rate and respiratory rates significantly dropped at 24 hrs. No statistically significant difference was noted between the mean pre-biopsy and the 1, 6, and 24-hrs post-biopsy values of blood pressure in all groups. The 24-hrs post-biopsy mean hemoglobin and hematocrit showed a significant decrease, while the 24-hrs post-biopsy mean total leucocyte and platelet counts showed non-significant changes. The 24-hrs post-biopsy mean liver enzymes were non-significantly changed except the 24-hrs post-biopsy mean PT which was found to be significantly prolonged, for a yet unknown reason(s).
Outpatient BPLB performed by the Menghini technique is safe and well tolerated even in infants and young children. Frequent, close monitoring of patients is strongly recommended to achieve optimal patient safety and avoid potential complications.
背景/目的:我们旨在研究门诊盲穿经皮肝活检(BPLB)在患有慢性肝病(CLD)的婴儿和儿童中的安全性。
使用 Menghini 抽吸技术对 80 名年龄在 2 个月至 14 岁的婴儿和儿童进行门诊 BPLB,以诊断其 CLD。患者分为三组:第 1 组(<1 岁)、第 2 组(1-6 岁)和第 3 组(6-14 岁)。在活检前 1 小时、活检后 1、2、6 和 24 小时密切监测生命体征。所有患者均在活检前 24 小时和后进行全血细胞计数、肝功能、凝血酶原时间(PT)和腹部超声检查,以寻找活检引起的血肿。
BPLB 后无死亡或严重并发症。轻微并发症发生率为 17.5%,包括 10%需要镇痛的烦躁或“疼痛”、5%轻度发热和 2.5%因过度镇静导致的嗜睡>6 小时。活检后 1 小时平均心率和呼吸率有统计学意义的升高,但在 6 小时和 24 小时时升高不显著,除第 2 组外,该组在 24 小时时心率和呼吸率显著下降。在所有组中,血压的平均术前值与 1、6 和 24 小时后活检值之间无统计学差异。所有组中,24 小时后血红蛋白和红细胞压积的平均水平显著下降,而白细胞和血小板计数的 24 小时后平均水平无显著变化。除 24 小时后 PT 显著延长外,24 小时后平均肝功能酶无显著变化,其原因(原因不明)尚不清楚。
采用 Menghini 技术进行门诊 BPLB 是安全且耐受良好的,即使在婴儿和幼儿中也是如此。强烈建议对患者进行频繁、密切的监测,以实现最佳的患者安全性并避免潜在的并发症。